Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Impact of TKI discontinuation in CML patients who have previously restarted TKI following allogeneic SCT

Retrospective Studies

Chronic Myeloid Leukaemia (CML)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Hugues de Lavallade

Analysis of Characteristics, Outcome and Risk Factors of Patients with Myelodysplastic Syndrome undergoing a Second Allogeneic Transplantation after Relapse from First AlloSCT

Retrospective Studies

Myelodysplastic (MDS) or MDS/MPN

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Giuliano Filippini Velazquez/Christoph Schmid

Development of a prognostic model for survival after allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelodysplastic neoplasms (MDS) using machine learning

Études rétrospectives

Syndrome Myélodysplasique (MDS) ou MDS/MPN

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Donal P. McLornan, Carmelo Gurnari, Adrián Mosquera Orgueira, Marie Robin

Development of a prognostic model for estimation of survival after allogeneic hematopoietic cell transplantation (allo-HCT) in patients Chronic Myelomonocytic Leukaemia utilizing Machine Learning

Retrospective Studies

Myelodysplastic (MDS) or MDS/MPN

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Marie Robin, Adrián Mosquera Orgueira, Francesco Onida, Carmelo Gurnari, Donal P. McLornan

A Retrospective analysis of transplantation outcome for individuals with Advanced Systemic Mastocytosis (Adv-SM): Aggressive Systemic Mastocytosis (ASM), SM with associated hematologic disease (SM-AHD), Mast-cell leukemia (MCL) and Mast cell Sarcoma (MCS)

Retrospective Studies

Myeloproliferative Neoplasm (MPN)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Comparative analysis of transplant outcomes with cryopreserved or fresh grafts in patients undergoing allogeneic hematopoietic transplantation for myelofibrosis

Retrospective Studies

Myeloproliferative Neoplasm (MPN)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Giorgia Battipaglia

Comparison of outcomes of myelofibrosis patients undergoing 1st matched sibling donor (MSD) allo- HCT receiving either PTCy based or other “conventional GVHD prophylaxis”

Retrospective Studies

Myeloproliferative Neoplasm (MPN)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Allogeneic - Related

Investigateur principal

Patrizia Chiusolo

Outcomes of Plasma Cell Myeloma Patients with t(4;14) who underwent Autologous Hematopoietic Cell Transplantation

Retrospective Studies

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Joanna Drozd-Sokolowska/Patrick Hayden

Outcomes of syngeneic transplants in multiple myeloma

Retrospective Studies

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Allogeneic - Related

Investigateur principal

Iman Abou Dalle/Ibrahim Yakoub-Agha

Del 17p Multiple myeloma (MM) patients who underwent autologous stem cell transplantation in EBMT centres between 2016 and 2022

Retrospective Studies

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Characteristics and outcomes of extramedullary myeloma receiving CAR-T cell therapy

Retrospective Studies

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Chronic Malignancies Working Party (CMWP)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Tomas Jelinek/Nico Gagelmann

Outcomes after anti-BCMA CAR T-cells for multiple myeloma, a Retrospective analysis on behalf of the CTIWP and CMWP of the EBMT

Études rétrospectives

Myélome multiple (MM) ou autre dyscrasies plasmocytaires (PCD)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal